Contemporary treatment patterns and survival of cervical cancer patients in Ethiopia.


Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
13 Oct 2021
Historique:
received: 11 02 2021
accepted: 31 08 2021
entrez: 14 10 2021
pubmed: 15 10 2021
medline: 11 1 2022
Statut: epublish

Résumé

Cervical cancer is the second commonly diagnosed cancer and the second leading cause of cancer death in women in Ethiopia, with rates among the highest worldwide. However, there are limited data on cervical cancer treatment patterns and survival in the country. Herein, we examine treatment patterns and survival of cervical cancer patients treated in Tikur Anbessa Hospital Radiotherapy Center (TAHRC), the only hospital with radiotherapy facility in the country. Women with histologically verified cervical cancer who were seen in 2014 (January 1, 2014 to December 31, 2014) at TAHRC were included. Information about clinical characteristics and treatments were extracted from the patients' medical record files. The information on vital status was obtained from medical chart and through telephone calls. Among 242 patients included in the study, the median age at diagnosis was 48 years. The median waiting time for radiotherapy was 5.6 months (range 2 to 9 months). Stage migration occurred in 13% of patients while waiting for radiotherapy. Consequently, the proportion of patients with stage III or IV disease increased from 66% at first consultation to 74% at the initiation of radiotherapy. Among 151 patients treated with curative intent, only 34 (22.5%) of the patients received concurrent chemotherapy while the reaming patients received radiotherapy alone. The 5-year overall survival rate was 28.4% (20.5% in the worst-case scenario). As expected, survival was lower in patients with advanced stage at initiation of radiotherapy and in those treated as palliative care. The survival of cervical cancer patients remains low in Ethiopia because of late presentation and delay in receipt of radiotherapy, leading to stage migration in substantial proportion of the cases. Concerted and coordinated multisectoral efforts are needed to promote early presentation of cervical cancer and to shorten the unacceptable, long waiting time for radiotherapy.

Sections du résumé

BACKGROUND BACKGROUND
Cervical cancer is the second commonly diagnosed cancer and the second leading cause of cancer death in women in Ethiopia, with rates among the highest worldwide. However, there are limited data on cervical cancer treatment patterns and survival in the country. Herein, we examine treatment patterns and survival of cervical cancer patients treated in Tikur Anbessa Hospital Radiotherapy Center (TAHRC), the only hospital with radiotherapy facility in the country.
METHODS METHODS
Women with histologically verified cervical cancer who were seen in 2014 (January 1, 2014 to December 31, 2014) at TAHRC were included. Information about clinical characteristics and treatments were extracted from the patients' medical record files. The information on vital status was obtained from medical chart and through telephone calls.
RESULT RESULTS
Among 242 patients included in the study, the median age at diagnosis was 48 years. The median waiting time for radiotherapy was 5.6 months (range 2 to 9 months). Stage migration occurred in 13% of patients while waiting for radiotherapy. Consequently, the proportion of patients with stage III or IV disease increased from 66% at first consultation to 74% at the initiation of radiotherapy. Among 151 patients treated with curative intent, only 34 (22.5%) of the patients received concurrent chemotherapy while the reaming patients received radiotherapy alone. The 5-year overall survival rate was 28.4% (20.5% in the worst-case scenario). As expected, survival was lower in patients with advanced stage at initiation of radiotherapy and in those treated as palliative care.
CONCLUSION CONCLUSIONS
The survival of cervical cancer patients remains low in Ethiopia because of late presentation and delay in receipt of radiotherapy, leading to stage migration in substantial proportion of the cases. Concerted and coordinated multisectoral efforts are needed to promote early presentation of cervical cancer and to shorten the unacceptable, long waiting time for radiotherapy.

Identifiants

pubmed: 34645407
doi: 10.1186/s12885-021-08817-1
pii: 10.1186/s12885-021-08817-1
pmc: PMC8515694
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1102

Informations de copyright

© 2021. The Author(s).

Références

J Clin Oncol. 1999 May;17(5):1339-48
pubmed: 10334517
Oncologist. 2018 Sep;23(9):1024-1032
pubmed: 29567823
Cancer Epidemiol. 2018 Apr;53:81-92
pubmed: 29414636
Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1246-1253
pubmed: 29395628
N Engl J Med. 1999 Apr 15;340(15):1154-61
pubmed: 10202166
Br J Cancer. 2009 Dec 3;101 Suppl 2:S102-9
pubmed: 19956153
Oncologist. 2014 Jul;19(7):727-34
pubmed: 24951611
Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1434-8
pubmed: 22806169
Int J Gynaecol Obstet. 2009 May;105(2):103-4
pubmed: 19367689
J Glob Oncol. 2016 Oct 12;3(5):635-657
pubmed: 29094101
PLoS One. 2013 Oct 30;8(10):e78411
pubmed: 24205226
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
BMC Cancer. 2020 Sep 1;20(1):830
pubmed: 32873252
J Glob Oncol. 2018 Sep;4:1-11
pubmed: 30241262
Lancet Oncol. 2013 Apr;14(4):289-90
pubmed: 23561741
N Engl J Med. 1999 Apr 15;340(15):1137-43
pubmed: 10202164
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
J Med Assoc Ga. 1974 Sep;63(9):357-61
pubmed: 4213347
Pan Afr Med J. 2014 Oct 31;19:234
pubmed: 25838862
J Surg Oncol. 1997 Oct;66(2):141-7
pubmed: 9354174

Auteurs

Biniyam Tefera Deressa (BT)

Adama Hospital Medical College, Adama, Ethiopia. biniyamtefera.md@gmail.com.

Mathewos Assefa (M)

Department of Clinical Oncology, College of Health Sciences, Addis Ababa university, Addis Ababa, Ethiopia.

Ephrem Tafesse (E)

College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.

Eva Johanna Kantelhardt (EJ)

Department of Gynaecology and Institute of Clinical Epidemiology, Martin Luther University, Halle an der Saale, Germany.

Ivan Soldatovic (I)

Institute of Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade, Beograd, Serbia.

Nikola Cihoric (N)

Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Daniel Rauch (D)

Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Ahmedin Jemal (A)

Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH